Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicits an antibody response that targets several viral proteins including spike (S) and nucleocapsid (N); S is the major target of neutralizing antibodies. Here, we assess levels of anti-N binding antibodies and anti-S neutralizing antibodies in unvaccinated children compared with unvaccinated older adults following infection. Specifically, we examine neutralization and anti-N binding by sera collected up to 52 weeks following SARS-CoV-2 infection in children and compare these to a cohort of adults, including older adults, most of whom had mild infections that did not require hospitalization. Neutralizing antibody titers were lower in children than adults early after infection, but by 6 months titers were similar between age groups. The neutralizing activity of the children’s sera decreased modestly from one to six months; a pattern that was not significantly different from that observed in adults. However, infection of children induced much lower levels of anti-N antibodies than in adults, and levels of these anti-N antibodies decreased more rapidly in children than in adults, including older adults. These results highlight age-related differences in the antibody responses to SARS-CoV-2 proteins and, as vaccines for children are introduced, may provide comparator data for the longevity of infection-elicited and vaccination-induced neutralizing antibody responses.


3
period. Neutralization titers for specimens collected at 8-to 13-weeks post-symptom onset (first 2 3 9 collection period) were previously reported using the same spike pseudotyped lentivirus 2 4 0 neutralization assay but without the D614G spike mutation (3). Here, we repeated the 2 4 1 neutralization assays using spike pseudotyped lentivirus encoding D614G as well as performing  in neutralization titer over the observation period, and no adults showed an increase greater than 2 4 7 4-fold. There were no adults for whom neutralization titers fell below the limit of detection 2 4 8 during the timeframe tested. For comparison of neutralization titers between the children and adults including older adults, we 2 5 0 restricted our analysis to only specimens collected in the same timeframe for both cohorts, as 2 5 1 well as only including children without immunocompromising conditions, those who did not 2 5 2 receive multiple blood transfusions, and those without MIS-C. In this sub-analysis, we found that greater than 4-fold are excluded, the children's GMT for the second collection period is 2.46-fold 2 5 9 lower than the adults' (123 compared to 302 in children and adults, respectively). We calculated 2 6 0 the fold change in titers for each individual measured at the first collection period relative to 2 6 1 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint 1 4 those measured for the same individual during the second time period. Fold change analysis was 2 6 2 limited to 5 children with specimens collected at both first and second collection period; no 2 6 3 difference in the fold change between children (geometric mean fold decrease = 1.12, N=6,) and 2 6 4 adults (geometric mean fold decrease = 1.28, N=14) was detectable (p = 0.893). (Figure 3C). with confirmed infection by RT-PCR (C1 and C32) did not have detected anti-N antibodies at 2 7 0 either timepoint. Anti-N antibody levels dropped considerably from a geometric mean index of 2 7 1 3.7 to 1.3 over 24 weeks. Eighteen of the 23 children, who were positive for anti-N antibodies at 2 7 2 the first collection period, exhibited a decrease in index values of greater than 2-fold, and an 2 7 3 additional five changed less than 2-fold. No children showed an increase in anti-N antibodies. In 4 weeks, values ranged from 1.9 to 8.0 and from undetectable to 7.3 by the first and second 2 7 7 collection periods, respectively.  The antibody dynamics out to 52-weeks post-symptom onset were measured for three children 2 8 1 all of whom had levels below the limit of detection by this later time period (Figure 4A, B, &C). CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint 1 5 Comparison of pediatric and adult anti-nucleocapsid antibody dynamics. Next, we 2 8 3 compared anti-N antibody dynamics in children and adults. We first measured anti-N antibody 2 8 4 levels for all adult specimens in our cohort (Supplemental figure 3). Overall, geometric mean 2 8 5 values in adults fell from 6.0 to 3.3 between the first and second collection period, respectively. One adult (A12) had values below the limit of detection at both 8-and 24-weeks post-symptom 2 8 7 onset. Of the adults with a positive index at 8 weeks, values ranged from 4.2 to 9.4 and from 1.9 2 8 8 to 7.7 by the first and second collection period, respectively. No adults with positive index values 2 8 9 at the first timepoint fell below the limit of detection by the later timepoint. This is in stark 2 9 0 contrast to the pediatric cohort where many fell below detectable levels over the course of the 2 9 1 study. Furthermore, only 3 adults showed a greater than 2-fold decrease in index values.

9 2
Compared to the pediatric cohort, adults had higher anti-N antibody levels at both timepoints 2 9 3 measured although not quite reaching statistical significance at 8-13 weeks (children: GMT = 2 9 4 4.7, range: 3.0-6.2; adults: GMT = 6.0, range: 0.8-9.4; p=0.053) ( Figure 5B). The difference 2 9 5 between adult and child index values was greatest at the later 24-to 29-week timepoint (children: antibodies may wane faster in children than adults. To test this, we compared the fold change 2 9 8 between the first and second collection periods in children and in adults. We found a greater 2 9 9 decrease for the pediatric cohort (geometric mean decrease of 4-fold) demonstrating that these 3 0 0 children lost N antibody binding at a faster rate than the adult cohort (geometric mean decrease  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint 1 6 In this study, we describe the kinetics of serum antibodies over time in children after infection 3 0 4 with SARS-CoV-2. In our convenience samples of unvaccinated children and adults with 3 0 5 confirmed or presumed SARS-CoV-2 infection, we found that pediatric serum neutralizing titers 3 0 6 were maintained over 24 weeks while anti-N-binding antibodies waned quickly. Importantly, 3 0 7 neutralizing antibody titers were highly variable among individual children as has been 3 0 8 previously observed in adults (1,3,6,8,10,11,23,24,45). Other studies have demonstrated that 3 0 9 greater disease severity and higher viral load are associated with higher antibody levels in adults  There are several reasons why antibody responses to SARS-CoV-2 infection could be different in children compared to adults, including disease typically being less severe in children (21, 47-3 1 8 51) as well as immune senescence and greater burden of comorbidities in older adults (52-58).

1 9
Further, primary infections with respiratory pathogens tend to occur early in life leaving  Interestingly, only a modest and non-significant decrease in neutralizing antibody level was 3 2 4 detected for pediatric specimens collected out to six months. A similar persistence in 3 2 5 . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint 1 7 neutralization potency was also observed in the adult cohort, suggesting that there might be long 3 2 6 term maintenance of neutralizing antibodies regardless of age following SARS-CoV-2 infection.

2 7
This finding is in line with several other bodies of work demonstrating the persistence of 3 2 8 neutralizing antibodies over many months (9,26,(59)(60)(61). We did, however, detect lower levels and other factors such as specimen collection time or disease severity could also contribute the 3 3 4 difference between this study and ours. Interestingly, by 24 weeks, a difference in neutralization 3 3 5 titers between children and adults was no longer detectable. This leveling of neutralization titers 3 3 6 over time has also been observed for some (3) but not all (11) studies of adults who have disease 3 3 7 of different severity: adults with severe disease have higher initial titers at early, but not later, and adults out to 60 days (24), and another study looking at only hospitalized children and adults 3 4 2 reported the same (63). However, one study (26) found that younger children had higher titers 3 4 3 than older children and adults. Differences in study population and sampling timepoints could 3 4 4 explain these differences. The most striking difference in SARS-CoV-2 antibody levels between children and adults was . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint Hughes Medical Institute. This material is based upon work supported by the National Science  funders had no role in study design, data collection, or the decision to submit the work for . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint  Pediatric study design, patient enrollment and data acquisition, and specimen collection were  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. Responses against SARS-CoV-2 Spike in Convalescent Individuals. mBio 11. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. Sci Immunol 5:eabe0367. Response to Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.

7
Clinical Infectious Diseases https://doi.org/10.1093/cid/ciaa1143.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint 2 3 Reich DL, Krammer F, Cordon-Cardo C. 2020. Robust neutralizing antibodies to SARS-CoV-2   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

2 3
. CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint magnitude and detectability are driven by disease severity, timing, and assay. Science Advances 5 3 0 7:eabh3409.  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint  . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ;https://doi.org/10.1101https://doi.org/10. /2022   . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint  CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

(which was not certified by peer review)
The copyright holder for this preprint this version posted January 25, 2022. . CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) The copyright holder for this preprint this version posted January 25, 2022. ; https://doi.org/10.1101/2022.01.14.22269235 doi: medRxiv preprint